Genomic Health, Inc. Announces Presentation of Six Studies at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium
REDWOOD CITY, Calif., Nov. 28, 2012 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will present results from six Oncotype® DX breast cancer test studies at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), taking place December 6-8, 2012 at the Henry B. Gonzalez Convention Center. Presentations include results from evaluations of the Oncotype DX breast cancer test's clinical utility and health economic value in various stages of early breast cancer including node-positive and node-negative disease as well as ductal carcinoma in situ (DCIS).
Following are details for each embargoed session (all times are in Central Standard Time):
Wednesday, December 5, 2012
- Abstract: S1-10
General Session 1: "Association between the 21-gene recurrence score (RS) and benefit from adjuvant paclitaxel (Pac) in node-positive (N+), ER-positive breast cancer patients (pts): Results from NSABP B-28"
Lead Author: Eleftherios P.Mamounas, M.D.
Location: Exhibit Hall D
Time: 10:45 a.m.
Thursday, December 6, 2012
- Abstract: P2-10-08
Poster Session 2 (Prognostic and Predictive Factors: Prognostic Factors Clinical):"Prospective comparison of Recurrence Score and different definitions of luminal subtypes by central pathology assessment of single markers in early breast cancer: results from the phase III WSG-planB Trial"
Lead Author: Oleg Gluz, M.D.
Location: Exhibit Halls A-B
Time:7:00 a.m. 9:00 a.m.
Friday, December 7, 2012
- Abstract: P5-15-01
Poster Session 5 (Psychosocial, Quality of Life, and Educational Aspects: Cost-Effectiveness):"Cost-effectiveness of gene expression profiling for ductal carcinoma in-situ (Oncotype DCIS Score)"
Lead Author: Michael Alvarado, M.D.
Location: Exhibit Halls A-B
Time: 5:00 p.m. 7:00 p.m. - Abstract: P5-15-06
Poster Session 5 (Psychosocial, Quality of Life, and Educational Aspects: Cost-Effectiveness):"Societal economics of the 21-gene Recurrence Score® in estrogen-receptor-positive early-stage breast cancer in Japan"
Lead Author: Hideko Yamauchi, M.D.
Location: Exhibit Halls A-B
Time: 5:00 p.m. 7:00 p.m. - Abstract: OT3-3-02
Poster Session 5 (Ongoing Trials 3: Chemotherapy):"ADAPT - Adjuvant Dynamic marker-Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer"
Lead Author: Oleg Gluz, M.D.
Location: Exhibit Halls A-B
Time: 5:00 p.m. 7:00 p.m.
Saturday, December 8, 2012
- Abstract: P6-07-03
Poster Session 5 (Prognostic and Predictive Factors: Prognostic and Predictive Factors Other):"Risk classification of Early Stage Breast Cancer as Assessed by MammaPrint and Oncotype DX Genomic Assays"
Lead Author: KrishnaClough, M.D.
Location: Exhibit Hall C
Time: 7:00 a.m. 8:30 a.m.
About Genomic Health
Genomic Health, Inc. (NASDAQ: GHDX) is a global healthcare company that provides actionable genomic information to personalize cancer treatment decisions. The company's lead product, the Oncotype DX® breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer and has been shown to predict the likelihood of recurrence in ductal carcinoma in situ (DCIS). In addition to this widely adopted test, Genomic Health provides the Oncotype DX colon cancer test, the first multi-gene expression test developed for the assessment of risk of recurrence in patients with stage II and stage III disease. As of September 30, 2012, more than 10,000 physicians in over 65 countries had ordered more than 320,000 Oncotype DX tests. Genomic Health has a robust pipeline focused on developing tests to optimize the treatment of prostate and renal cell cancers, as well as additional treatment decisions in breast and colon cancers. The company is based in Redwood City, California with European headquarters in Geneva, Switzerland. For more information, please visit, www.GenomicHealth.com. To learn more about Oncotype DX tests, visit: www.OncotypeDX.com and www.mybreastcancertreatment.org.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the attributes and focus of the company's product pipeline, the outcome of future studies; the ability of the company to develop additional tests in the future, the demand for the Company's products, and the ability of any potential tests the company may develop to optimize cancer treatment. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and uncertainties associated with the regulation of the company's tests; the results of clinical studies; the applicability of clinical study results to actual outcomes; our ability to develop and commercialize new tests; unanticipated costs or delays in research and development efforts; our ability to obtain capital when needed and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Annual Report on Form 10-Q for the quarter ended September 30, 2012. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.
NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, and DCIS Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.
SOURCE Genomic Health, Inc.